Showing results for:
Axatilimab-csfr is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (about 88 pounds).
Axatilimab-csfr Niktimvo™
Filgrastim is FDA approved to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with feverReduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresisReduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropeniaIncrease survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
Neupogen® Filgrastim G-CSF Zarxio™ * Filgrastim-sndz* Nivestym™ * Filgrastim-aafi* Releuko* Filgrastim-ayow*
Granulocyte Colony-Stimulating and Granulocyte-Macrophage Colony-Stimulating Growth Factors
Filgrastim, pegfilgrastim and sargramostim are synthetic versions of substances naturally produced in your body. They are FDA approved to prevent or reduce the risk of infection for patients with nonmyeloid malignancies who are being treated with anti-inflammatory drugs that inhibit blood cell production and are associated with severely low counts of certain white blood cells (neutropenia). Colony-stimulating growth factors may also be used to help the marrow recover after stem cell transplantation. Sargramostim is FDA approved to increase survival in adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS).
Neupogen® G-CSF Granulocyte Colony-Stimulating and Granulocyte-Macrophage Colony-Stimulating Growth Factors
Ixazomib is FDA approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
NINLARO® Ixazomib
Mechlorethamine is FDA approved to treat people who have Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphocytic leukemia, polycythemia vera and mycosis fungoides.
Mustargen® nitrogen mustard Mechlorethamine
Mitoxantrone is FDA approved in combination with other approved drug(s) indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. Mitoxantrone is a dark blue solution that may cause urine to appear blue-green. It may also cause the whites of the eyes to turn a blue color. These effects are normal and last for only 1 or 2 days after each dose is given. This medicine often causes a temporary loss of hair. After treatment with mitoxantrone has ended, normal hair growth should return.
Novantrone® Mitoxantrone
Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.
Arranon® Nelarabine
Tasigna® is FDA approved for the treatment ofAdult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.Danziten™ is FDA approved for the treatment ofAdult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.Eligible newly diagnosed patients with Ph+ CML-Chronic Phase who have received nilotinib for a minimum of 3 years and have achieved a sustained molecular response (MR4.5) and patients with Ph+ CML-Chronic Phase resistant or intolerant to imatinib who have received nilotinib for at least 3 years and have achieved a sustained molecular response (MR4.5) may be considered for treatment discontinuation.
Tasigna® Nilotinib
Nivolumab is FDA approved for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Opdivo® Nivolumab
Pegfilgrastim is FDA approved toDecrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).Limitations of Use: Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation
Neulasta® Pegfilgrastim G-CSF Fulphila™ * Pegfilgrastim-jmdb* Udenyca™ * Pegfilgrastim-cbqv* Ziextenzo™ * Pegfilgrastim-bmez * Nyvepria Pegfilgrastim-apgf* Fylnetra* Pegfilgrastim-pbbk* Stimufend®* Pegfilgrastim-fpgk*
Pentostatin is FDA approved as a single-agent treatment for both untreated and alfa-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia (abnormally low white blood count), thrombocytopenia (reduced platelet count), or disease-related symptoms.
Nipent® Pentostatin